Vimarsana
Biggest News Aggregation in the World

Page 3 - Dror Harats News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Dror Harats. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Dror Harats Today - Breaking & Trending Today

VBL Therapeutics Selected for €17.5 Million of Funding from Horizon Europe EIC Accelerator Program - Vimarsana News

VBL Therapeutics Selected for €17.5 Million of Funding from Horizon Europe EIC Accelerator Program

VBL Therapeutics Selected for €17.5 Million of Funding from Horizon Europe EIC Accelerator Program - read this article along with other careers information, tips and advice on BioSpace

Lonza and Sheba Medical Center Use Cocoon® Platform and Show Successful Clinical Outcomes in Patients Treated with CAR-T Cell Immunotherapy, Lonza Group Ltd., Pressemitteilung - Vimarsana News

Lonza and Sheba Medical Center Use Cocoon® Platform and Show Successful Clinical Outcomes in Patients Treated with CAR-T Cell Immunotherapy, Lonza Group Ltd., Pressemitteilung

Lonza Group Ltd., Four patients have been successfully dosed at Sheba Medical Center, Israel, with a CD19 autologous CAR-T cell therapy u…

Source: lifepr.de
Immunotherapy Using Immune-Checkpoint Inhibitors (ICI) Modulators Are Revolutionizing Oncology Industry - Vimarsana News

Immunotherapy Using Immune-Checkpoint Inhibitors (ICI) Modulators Are Revolutionizing Oncology Industry

Share this article Share this article PALM BEACH, Fla., Jan. 25, 2021 /PRNewswire/ -- Ovarian cancer is one of the most deadly gynecologic malignancy across the globe, but new treatments are gaining increased efficacy while displaying reduced toxicity. Clinical trials abound. Immunotherapy using immune-checkpoint modulators has been revolutionizing the oncology field far beyond their remarkable clinical efficacy in some patients. It creates radical changes in the evaluation of treatment efficacy and toxicity with a more holistic vision of the patient with cancer. An article in Nature.com rec...

VBL Therapeutics Announces First Patient in Europe in the OVAL Trial - Vimarsana News

VBL Therapeutics Announces First Patient in Europe in the OVAL Trial

[December 29, 2020] VBL Therapeutics Announces First Patient in Europe in the OVAL Trial Expands OVAL Phase 3 Potential Registration Study of VB-111 for the Treatment of Platinum-Resistant Ovarian Cancer into Europe  TEL AVIV, Israel, Dec. 29, 2020 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT) today announced the expansion of its ongoing OVAL Phase 3 study investigating ofranergene obadenovec (VB-111), for the treatment of platinum-resistant ovarian cancer into Europe, where the first patient has now been enrolled. The study continues to actively recruit patients in the U.S. an...

Source: tmcnet.com